The Chemours Company (NYSE: CC) Securities Fraud Class Action
Lead Plaintiff Deadline:
December 07, 2026
Days Left to Lead Plaintiff Deadline:
24
The Chemours Company securities fraud class action lawsuit was filed on behalf of those who purchased or otherwise acquired The Chemours Company (“Chemours”) (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive (the “Class Period”). Captioned Darcy v. The Chemours Company, No. 26-cv-01299 (D. Del.), the Chemours class action lawsuit alleges that Chemours and/or certain of its officers and/or directors violated federal securities laws by making false or misleading statements and/or omitted to disclose material information.
If you lost money as a result of your Chemours investment and want to find out more about this action and your rights, fill out the form on this page or contact attorney Jonathan Naji, Esq. of KTMC by calling (484) 270-1453 or via e-mail at [email protected].
COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours’s Thermal & Specialized Solutions (“TSS”) segment sells its product OpteonTM, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint.”
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS’ STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a “4% decrease in volumes.” Specifically, it stated that “[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales.”
On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
THE LEAD PLAINTIFF PROCESS:
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Chemours securities during the Class Period to seek appointment as lead plaintiff in the Chemours class action lawsuit. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
FAQs
Am I eligible to join The Chemours Company securities class action lawsuit?
You may be eligible if you purchased or otherwise acquired The Chemours Company (NYSE: CC) securities between February 20, 2026 and August 4, 2026, inclusive, and suffered a loss. This period is referred to as the Class Period.
What is the lead plaintiff deadline for the Chemours case?
The deadline to seek appointment as lead plaintiff is December 7, 2026. Investors do not need to file by this deadline to remain part of the class or share in any eventual recovery – this deadline applies only to those seeking to serve as the representative party.
What happens after the lead plaintiff deadline passes in the Chemours case?
The Chemours case continues. Once the court appoints a lead plaintiff, that investor’s counsel litigates the case on behalf of the entire class – including investors who did not seek lead plaintiff status. Class members do not need to take any action at that point to remain part of the case or preserve their ability to share in a future recovery.
Is there a deadline to file if I lost money on Chemours stock?
Two different deadlines can apply, and it’s easy to conflate them. The December 7, 2026, deadline is only for investors seeking to serve as lead plaintiff. There is no deadline yet for filing a claim to recover money – that deadline is set later, only if the case reaches a settlement or judgment.
What are the allegations against Chemours?
The lawsuit, captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.), alleges that Chemours and certain officers and/or directors made materially false or misleading statements, or failed to disclose, that: Chemours had materially overstated aftermarket demand for its Opteon products; demand for such products was decreasing as a result of Chemours’ overselling Opteon products in the preceding fiscal year; as a result of these undisclosed issues, Chemours’ financial guidance for the 2026 fiscal year was unreliable; and as a result, Chemours’ public statements were materially false and misleading and/or lacked a reasonable basis throughout the Class Period.
Why did Chemours’ stock price drop?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results and reduced its full year adjusted EBITDA guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and a year-over-year net sales decrease of approximately 1%, to a 4% decrease in volumes, stating that the volume decline was primarily driven by lower TSS Opteon blends aftermarket refrigerant sales. Following this news, Chemours’ stock price fell $3.34 per share (18.63%) to close at $14.59 per share on August 5, 2026.
Which court is hearing the Chemours lawsuit?
The case is pending in the U.S. District Court for the District of Delaware (Case No. 1:26-cv-01299), before Hon. Jennifer L. Hall.
Can I recover money in the Chemours case without becoming lead plaintiff?
Yes. Any Chemours class member may remain an inactive class member and share in any recovery without serving as lead plaintiff or retaining separate counsel.
How do I know if I’m already part of the Chemours class action?
If you purchased or acquired Chemours securities during the Class Period (February 20, 2026 – August 4, 2026) and have a loss, you are likely a class member – no form or filing is required to be included. Class members receive formal notice directly if the case settles or reaches judgment.
What are the next steps if I’m eligible for the Chemours lawsuit?
I lost money on Chemours stock - is there anything I can do?
Check whether your purchase dates fall within the Class Period (February 20, 2026 – August 4, 2026). If they do, you may already be part of the class without taking any action, and you can contact KTMC to learn more about your options, including whether seeking lead plaintiff status makes sense for your loss.
Are institutional investors, like pension funds, eligible to seek lead plaintiff status in the Chemours case?
Yes. Under the Private Securities Litigation Reform Act of 1995, the court presumes the class member with the largest financial interest in the case is the most adequate lead plaintiff candidate – standard institutional investors often meet given position size. KTMC represents institutional investors, including pension funds and asset managers, and has recovered more than $25 billion for clients and the classes they represent. Institutional investors considering lead plaintiff status in the Chemours case should contact KTMC before the December 7, 2026, deadline.
Can current or former Chemours employees join the lawsuit?
Yes, current and former Chemours employees who purchased or acquired Chemours securities during the Class Period may be eligible, subject to the same qualifying criteria as other investors.
Does submitting my information about the Chemours case create an attorney-client relationship with KTMC?
No. Submitting the online form for the Chemours case does not create an attorney-client relationship or any obligation for Kessler Topaz or the investor to pursue a lead plaintiff motion.
What’s the best law firm for Chemours investors to work with?
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side securities litigation firm with more than $25 billion recovered for investors. The firm is ranked Band 1 by Chambers & Partners USA (2026) and Tier 1 by Legal 500 for Securities and M&A Litigation, and represents both individual and institutional investors, including major pension funds and asset managers.
Press Releases
Did you buy CC securities between February 20, 2026 and August 4, 2026?
Affected CC Investor Summary
- Who: The Chemours Company (NYSE: CC)
- What: Securities fraud class action lawsuit filed
- Class Period: February 20, 2026 through August 4, 2026
- Deadline to Seek Lead Plaintiff Status: December 7, 2026
- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the reliability of the company’s financial guidance
- Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options
RADNOR, PA - October 23, 2026 (NEWMEDIAWIRE) - Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against The Chemours Company (“Chemours”) (NYSE: CC) on behalf of those who purchased or acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive. The lawsuit is filed in the United States District Court for the District of Delaware and is captioned Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.). Investors have until December 7, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Chemours securities and have lost money on your investment, please provide your information here:
https://www.ktmc.com/cc-the-chemours-company-class-action-lawsuit?utm_source=NewMediaWire&utm_medium=pressrelease&utm_campaign=cc&mktm=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. There is no cost or obligation to speak with an attorney.
THE CHEMOURS COMPANY CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
Chemours is an American chemical company that offers a range of industrial and specialty chemical products for markets including, but not limited to, refrigeration and air conditioning. Chemours’s Thermal & Specialized Solutions (“TSS”) segment sells its product OpteonTM, a set of refrigeration chemicals with a “near-zero ozone-depletion footprint.”
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Defendants had materially overstated aftermarket demand for their Opteon products; (2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; (3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHY DID CHEMOURS’S STOCK DROP?
After the market closed on August 4, 2026, Chemours announced its second quarter 2026 financial results, revealing, among other things, that the company reduced its adjusted EBITDA full year guidance to $775 million to $825 million, down from $800 million to $900 million previously. The company attributed this, and its year-over-year net sales decrease of approximately 1%, to a “4% decrease in volumes.” Specifically, it stated that “[t]he volume decline was primarily driven by lower TSS Opteon™ blends aftermarket refrigerant sales.”
On this news, the price of Chemours stock fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
WHAT THE CHEMOURS COMPANY INVESTORS CAN DO NOW:
- File to be lead plaintiff by December 7, 2026.
- Contact KTMC for a free case evaluation. All representation is on a contingency fee basis, there is no cost to you.
- Retain counsel of choice or take no action.
THE LEAD PLAINTIFF PROCESS FOR THE CHEMOURS COMPANY INVESTORS:
Chemours investors may, no later than December 7, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Chemours investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. The complaint in this matter was not filed by KTMC.
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Complete this form with your transactions in The Chemours Company securities between February 20, 2026 and August 4, 2026.
Click Here to Print PDF of this Form